RCUS Arcus Biosciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why RCUS matters now
Arcus Biosciences, Inc. (RCUS) is a US stock in Healthcare. The latest InvestLog snapshot shows $28.92 with -3.47% on the session and $2.91B in market capitalization; recent performance reads 1-month +6.86% and YTD +2.01%.
The latest financial table shown here is Q1 2026, with revenue of $17.0M, net income of $-128.0M, and EPS of $-1.02. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -20.0%.
The latest indexable market news headline is "Arcus Biosciences Announces New Employment Inducement Grants" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $28.00; recent insider activity includes PERLMAN ANDREW J filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.82
P/S
10.37
EV/EBITDA
-7.15
DCF Value
$-38.89
FCF Yield
-20.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.0%
Operating Margin
-168.6%
Net Margin
-156.4%
ROE
-69.0%
ROA
-37.0%
ROIC
-49.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.0M | $-128.0M | $-1.02 |
| Q4 2025 | $33.0M | $-98.0M | $-0.92 |
| FY 2025 | $247.0M | $-353.0M | $-3.29 |
| Q3 2025 | $26.0M | $-135.0M | $-1.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$31.00
Target (Median)
$28.00
Target Range
$22.00 - $47.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug candidates: Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is currently in Phase 1b/2 clinical trials. Zimberelimab, an anti-PD-1 antibody, is being evaluated as a monotherapy in Phase 1b studies. Another key asset is Domvanalimab, an anti-TIGIT monoclonal antibody, undergoing Phase 2 development for first-line metastatic non-small cell lung cancer when administered with Zimberelimab. The company is also developing Quemliclustat, a small-molecule CD73 inhibitor, in Phase 1/1b studies for the initial treatment of metastatic pancreatic cancer. AB521, an oral small molecule HIF-2a inhibitor, is in Phase 1 trials for patients with von Hippel-Lindau disease. Arcus actively collaborates with other entities to advance its programs. It has a clinical development partnership with Strata Oncology, Inc. to assess Zimberelimab. Furthermore, a significant collaboration with AstraZeneca and BVF Partners L.P. is underway for a registrational Phase 3 clinical trial, testing Domvanalimab (an experimental anti-TIGIT antibody) alongside Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer. Additionally, Arcus holds licensing agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics for the development of an anti-CD39 antibody targeting various cancers. Incorporated in 2015, the company's corporate headquarters are located in Hayward, California.